+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

A novel oncolytic herpes simplex virus type 2 has potent anti-tumor activity



A novel oncolytic herpes simplex virus type 2 has potent anti-tumor activity



Plos One 9(3): E93103



Oncolytic viruses are promising treatments for many kinds of solid tumors. In this study, we constructed a novel oncolytic herpes simplex virus type 2: oHSV2. We investigated the cytopathic effects of oHSV2 in vitro and tested its antitumor efficacy in a 4T1 breast cancer model. We compared its effect on the cell cycle and its immunologic impact with the traditional chemotherapeutic agent doxorubicin. In vitro data showed that oHSV2 infected most of the human and murine tumor cell lines and was highly oncolytic. oHSV2 infected and killed 4T1 tumor cells independent of their cell cycle phase, whereas doxorubicin mainly blocked cells that were in S and G2/M phase. In vivo study showed that both oHSV2 and doxorubicin had an antitumor effect, though the former was less toxic. oHSV2 treatment alone not only slowed down the growth of tumors without causing weight loss but also induced an elevation of NK cells and mild decrease of Tregs in spleen. In addition, combination therapy of doxorubicin followed by oHSV2 increased survival with weight loss than oHSV2 alone. The data showed that the oncolytic activity of oHSV2 was similar to oHSV1 in cell lines examined and in vivo. Therefore, we concluded that our virus is a safe and effective therapeutic agent for 4T1 breast cancer and that the sequential use of doxorubicin followed by oHSV2 could improve antitumor activity without enhancing doxorubicin's toxicity.

(PDF emailed within 0-6 h: $19.90)

Accession: 051198643

Download citation: RISBibTeXText

PMID: 24671154

DOI: 10.1371/journal.pone.0093103


Related references

Stability and anti-tumor effect of oncolytic herpes simplex virus type 2. Oncotarget 9(37): 24672-24683, 2018

IL-12 Expressing oncolytic herpes simplex virus promotes anti-tumor activity and immunologic control of metastatic ovarian cancer in mice. Journal of Ovarian Research 9(1): 70, 2016

An oncolytic virus derived from type 2 herpes simplex virus has potent therapeutic effect against metastatic ovarian cancer. Cancer Gene Therapy 14(5): 480-487, 2007

Virotherapy with a type 2 herpes simplex virus-derived oncolytic virus induces potent antitumor immunity against neuroblastoma. Clinical Cancer Research 13(1): 316-322, 2007

A mutant type 2 herpes simplex virus deleted for the protein kinase domain of the ICP10 gene is a potent oncolytic virus. Molecular Therapy 13(5): 882-890, 2006

Potent systemic antitumor activity from an oncolytic herpes simplex virus of syncytial phenotype. Cancer Research 62(8): 2306-2312, 2002

Vaccinia virus recombinant that expresses the herpes simplex virus type 1 glycoprotein d gene protects mice against lethal challenge by herpes simplex virus type 1 or herpes simplex type 2 and the establishment of a latent ganglionic infection by herpes simplex virus type 1. Lerner, R A , R M Chanock And F Brown (Ed ) Vaccines 85: Molecular And Chemical Basis Of Resistance to Parasitic, Bacterial, And Viral Diseases; Meeting, 1983 Xxi+407p Cold Spring Harbor Laboratory: Cold Spring Harbor, N Y , Usa Illus Paper 169-174, 1985

Destruction of nonimmunogenic mammary tumor cells by a fusogenic oncolytic herpes simplex virus induces potent antitumor immunity. Molecular Therapy 9(5): 658-665, 2004

Potent oncolytic activity of multimutated herpes simplex virus G207 in combination with vincristine against human rhabdomyosarcoma. Cancer Research 63(7): 1508-1514, 2003

Oncolytic herpes simplex virus type-1 vector with anti-K-ras antisense oligonucleotides. Proceedings of the American Association for Cancer Research Annual Meeting 42: 31, March, 2001

ICP345 deleted Herpes Simplex Virus 1 with enhanced oncolytic and anti-tumor potential Development of novel replicating vectors for tumor therapy. Proceedings of the American Association for Cancer Research Annual Meeting 43: 1097, March, 2002

Development of a regulatable oncolytic herpes simplex virus type 1 recombinant virus for tumor therapy. Journal of Virology 84(16): 8163-8171, 2010

Anti-tumor effect of oncolytic herpes simplex virus G47delta on human nasopharyngeal carcinoma. Chinese Journal of Cancer 30(12): 831-841, 2013

Passive transfer of anti-herpes simplex virus type 2 monoclonal and polyclonal antibodies protect against herpes simplex virus type 1-induced but not herpes simplex virus type 2-induced stromal keratitis. Investigative Ophthalmology & Visual Science 34(8): 2460-2468, 1993

Potent antitumor activity after systemic delivery of a doubly fusogenic oncolytic herpes simplex virus against metastatic prostate cancer. Prostate 60(1): 53-60, 2004